{"id":"a166","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":{"chemblId":"CHEMBL5739942","moleculeType":null,"molecularWeight":"433.52"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting the PD-L1/PD-1 axis, A166 removes the immunosuppressive signal that tumors use to evade T-cell recognition and killing. This checkpoint inhibition allows cytotoxic T lymphocytes to recognize and eliminate cancer cells more effectively. The drug is being developed by Sichuan Kelun-Biotech as a potential immunotherapy for various solid tumors.","oneSentence":"A166 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:58:28.055Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07299825","phase":"PHASE2","title":"A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2024-09-20","conditions":"Her 2 Positive Breast Cancer","enrollment":40},{"nctId":"NCT05311397","phase":"PHASE1","title":"A Study of A166 in Patients With Advanced Solid Malignant Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2018-08-09","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT06968585","phase":"PHASE3","title":"A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","startDate":"2023-07-18","conditions":"HER2-positive Breast Cancer","enrollment":365},{"nctId":"NCT03602079","phase":"PHASE1, PHASE2","title":"Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene","status":"COMPLETED","sponsor":"Klus Pharma Inc.","startDate":"2018-07-16","conditions":"HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification","enrollment":49},{"nctId":"NCT05346328","phase":"PHASE2","title":"HER2-positive Breast Cancer Project Initiated by Investigators","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2022-06-01","conditions":"Breast Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":27,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"A166","genericName":"A166","companyName":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","companyId":"sichuan-kelun-biotech-biopharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A166 is an anti-PD-L1 monoclonal antibody that blocks the interaction between PD-L1 on tumor cells and PD-1/B7.1 on immune cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}